The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development. For more information, visit www.avantgen.com.

Licensing 52

Licensing Licensing Therapies Engineering 52

The Pharma Data

DECEMBER 13, 2020

Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the company conducted a Type B Meeting for omidubicel with the U.S. For more information on clinical trials of omidubicel, please visit www.clinicaltrials.gov. Source link.

Licensing 52

Licensing Licensing Clinical Trials FDA 52

The Pharma Data

DECEMBER 20, 2020

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Licensing 40

Licensing Licensing Pharmaceuticals Pharmaceutical Companies 40

The Pharma Data

DECEMBER 16, 2020

NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., The agreement leverages Otsuka’s well-recognized expertise in rare kidney diseases to underscore Aurinia’s commitment to expanding global access to voclosporin for the treatment of LN.

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. This information was brought to you by Cision [link].

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

The Pharma Data

DECEMBER 20, 2020

Interventional treatment for mitral regurgitation is considered to be one of the most challenging areas in the field of structural heart disease, yet also represents huge market potential. The terms also allow cross-licensing on future improvements of the products, encouraging both companies to focus on innovations. About HighLife.

Licensing 40

Licensing Licensing Production Treatment 40

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). For more information, please visit [link]. About Biohaven.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

AUGUST 17, 2020

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. About Dragonfly.

Licensing 52

Licensing Licensing Production Clinical Trials 52

The Pharma Data

MARCH 22, 2021

Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the decision to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington’s disease (HD). In December 2017, Roche licensed the investigational molecule from Ionis Pharmaceuticals. About Huntington’s disease.

Disease 52

Disease Clinical Trials Pharmacokinetics Treatment 52

The Pharma Data

MARCH 30, 2021

Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. Source link:[link].

Therapies 52

Therapies Licensing Licensing Protein Expression 52

The Pharma Data

NOVEMBER 6, 2020

The Advisory Committee also voted 0 yes, 7 no and 4 uncertain on the question, “Does Study 103 (PRIME) provide supportive evidence of the effectiveness of aducanumab for the treatment of Alzheimer’s disease?”, Aducanumab (BIIB037) is an investigational human monoclonal antibody studied for the treatment of Alzheimer’s disease.

Disease 40

Disease FDA Clinical Trials Licensing 40

The Pharma Data

MAY 4, 2021

Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic.

Licensing 40

Licensing Licensing Therapies Laboratories 40

The Pharma Data

OCTOBER 27, 2020

Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease (RPD) designations to PBKR03 for the treatment of Krabbe disease (Globoid Cell Leukodystrophy). About Krabbe Disease. Passage Bio expects to initiate a Phase 1/2 trial for PBKR03 in the first half of 2021.

Disease 40

Disease FDA Treatment Clinical Trials 40

Drug Target Review

OCTOBER 10, 2024

What are the risks of over-reliance on healthy donor material in early-stage research, and how can decision-makers ensure a balanced integration of diseased material to avoid potential gaps when transitioning to clinical trials? Diseased cells are likely to be more fragile or less abundant, making it difficult to obtain enough for therapy.

Therapies 52

Therapies Immune Response Clinical Trials Disease 52

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China. 1 Kratz et al.,

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

OCTOBER 29, 2020

If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and to meaningfully change the course of Alzheimer’s disease. If approved, aducanumab would become the first therapy to reduce the clinical decline in patients with Alzheimer’s disease. CAMBRIDGE, Mass.

Disease 40

Disease Marketing Clinical Trials Treatment 40

DrugBank

AUGUST 15, 2024

An example is the collaboration between Novartis and the University of Oxford to develop a gene therapy for spinal muscular atrophy, a rare genetic disease. This is particularly important in the context of neurodegenerative diseases, where the burden on healthcare systems is significant and growing.

Drug Development 80

Drug Development Clinical Trials Drugs Therapies 80

The Pharma Data

JANUARY 18, 2021

The funds will be used to advance its nose-on-chip platform to detect the characteristic smell linked to Parkinson’s disease (PD). Yesse Technologies scientists recently validated the presence of a distinctive smell, arising from an oily skin secretion called sebum, in patients diagnosed with Parkinson’s disease.

Disease 40

Disease Molecular Biology Licensing Licensing 40

The Pharma Data

MAY 2, 2022

– Gilead to License Exclusive Worldwide Rights to the Investigational Candidate DF7001, a 5T4-Targeting NK Cell Engager for Solid Tumors –. – Gilead to Have Options to License Several Additional NK Cell Engager Programs –. For more information visit: www.dragonflytx.com [link] [link]. Gilead Sciences, Inc.

Licensing 52

Licensing Licensing Research Protein Expression 52

The Pharma Data

SEPTEMBER 10, 2021

Abrocitinib is licensed in Great Britain in recommended doses of 100mg and 200mg. This is an important development for people in Great Britain who have moderate to severe disease and need innovative treatment options,” said Angela Hwang, Group President, Pfizer Biopharmaceuticals Group. SAFETY INFORMATION. Five placebo?controlled

Marketing 52

Marketing Licensing Licensing Small Molecule 52

The Pharma Data

JANUARY 18, 2021

Potential first-in-class disease-modifying biologic in late-stage clinical studies. a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingworth LLP.

Disease 52

Disease Science Clinical Development Treatment 52

The Pharma Data

MARCH 5, 2021

Biogen (Nasdaq: BIIB) today announced it will host webcasts of its pre-recorded presentations and live discussions related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming AD/PDTM 2021 Virtual Conference. We routinely post information that may be important to investors on our website at www.biogen.com.

Licensing 52

Licensing Licensing Biosimilars Disease 52

New Drug Approvals

SEPTEMBER 8, 2024

4] [6] The applicant for this medicinal product is Ascendis Pharma Bone Diseases A/S. [4] Reproduction is authorized provided the source is acknowledged. ^ “Yorvipath Product information” Union Register of medicinal products. Palopegteriparatide is a pegylated synthetic peptide (molecular weight: ca. 14 August 2024.

FDA 62

FDA International Trials FDA Approval 62

The Pharma Data

NOVEMBER 25, 2020

CAN10 has been designed to block the signalling of the inflammatory cytokines IL-1, IL-33 and IL-36 resulting in unique properties for treatment of inflammatory diseases. More information is available at www.bioinvent.com. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

Drug Target Review

OCTOBER 14, 2024

His current role at Mironid focuses on developing treatments for rare genetic kidney diseases, and his insights reveal the challenges and potential of integrating advanced technologies like artificial intelligence (AI) into the drug discovery process.

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

The Pharma Data

JANUARY 12, 2021

LONDON, UK / ACCESSWIRE / January 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company (“GlobalCo”).

Pharmaceuticals 40

Pharmaceuticals Licensing Licensing Clinical Trials 40

DrugBank

FEBRUARY 9, 2023

disease genes) generated from patients inflicted with both obesity and type 2 diabetes, were mapped to tissue-specific protein–protein interactome and gene coexpression network to generate tissue-specific disease modules. With both paid and free academic licenses available, there are options to suit all of your research needs.

Clinical Pharmacology 52

Clinical Pharmacology Molecular Biology DNA Licensing 52

The Pharma Data

APRIL 12, 2023

Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ). Accumulation of Aβ plaque in the brain is a defining feature of Alzheimer’s disease (AD). (Nasdaq: BIIB) and Denali Therapeutics Inc.

Engineering 40

Engineering Licensing Licensing Treatment 40

New Drug Approvals

SEPTEMBER 6, 2024

2 History Efficacy was evaluated in MARIPOSA (NCT04487080), a randomized, active-controlled, multicenter trial of 1074 participants with exon 19 deletion or exon 21 L858R substitution mutation-positive locally advanced or metastatic non-small cell lung cancer and no prior systemic therapy for advanced disease. [2] 20 August 2024. .

FDA Approval 62

FDA Approval FDA International Treatment 62

The Pharma Data

NOVEMBER 23, 2020

NYSE American: SYN) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com. . .

Compliance 52

Compliance Licensing Licensing Clinical Trials 52

The Pharma Data

JUNE 24, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older. AUTHORIZED USE IN THE U.S.:

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

JANUARY 4, 2021

The program was licensed to Allergan in April 2016 , and Allergan was acquired by AbbVie in May 2020. We enjoyed a productive relationship with Allergan over the course of our muscarinic agonist collaboration and continue to work positively with AbbVie on a new program in inflammatory diseases that we announced in June last year.

Licensing 40

Licensing Licensing Clinical Trials Disease 40

Policy Prescription

MAY 28, 2021

That New York Times piece included the following parenthetical disclaimer: “(My company, PharmacyChecker.com, helps Americans find information on obtaining lower-cost medications from Canada and other countries, so I have a financial stake in making sure the public is informed.)” and licensed by your state board of pharmacy.”

Pharmacy 52

Pharmacy Licensing Licensing Online Pharmacies 52

Agency IQ

MAY 28, 2024

New FDA guidance on addressing misinformation under White House review A new question-and-answer draft guidance document focused on “addressing misinformation” about regulated life sciences products is currently under administrative review at the White House’s Office of Information and Regulatory Affairs (OIRA).

FDA 40

FDA Regulations Production Licensing 40

The Pharma Data

AUGUST 15, 2021

Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) is expected to discuss recommendations on the safe and appropriate use of TICOVAC. “We Important Safety Information for TICOVAC. Please see full prescribing information for TICOVAC here. Global President, Vaccines, Pfizer.

FDA Approval 52

FDA Approval Vaccine FDA Virus 52

Agency IQ

JUNE 28, 2024

BY AMANDA CONTI | JUN 26, 2024 8:51 PM CDT Quick regulatory background: The FDA’s role in ensuring accurate information about regulated products The FDA is responsible for ensuring that medical products are adequately labeled in accordance with federal regulations, including the product’s “intended use” and relevant safety information.

FDA 40

FDA Regulations Production Licensing 40

The Pharma Data

NOVEMBER 29, 2020

HK) is a globally, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and age-related diseases. The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. SUZHOU, China and ROCKVILLE, Md. ,

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40